These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32685378)

  • 1. Cystinosis: Therapy adherence and metabolic monitoring in patients treated with immediate-release cysteamine.
    Linden S; Klank S; Harms E; Grüneberg M; Park JH; Marquardt T
    Mol Genet Metab Rep; 2020 Sep; 24():100620. PubMed ID: 32685378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis.
    van Stein C; Klank S; Grüneberg M; Ottolenghi C; Grebe J; Reunert J; Harms E; Marquardt T
    Orphanet J Rare Dis; 2021 Sep; 16(1):387. PubMed ID: 34521447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enteric-Coated Cysteamine Bitartrate in Cystinosis Patients.
    Klank S; van Stein C; Grüneberg M; Ottolenghi C; Rauwolf KK; Grebe J; Reunert J; Harms E; Marquardt T
    Pharmaceutics; 2023 Jun; 15(7):. PubMed ID: 37514038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.
    Ahlenstiel-Grunow T; Kanzelmeyer NK; Froede K; Kreuzer M; Drube J; Lerch C; Pape L
    Pediatr Nephrol; 2017 Jan; 32(1):91-97. PubMed ID: 27350621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety.
    Langman CB; Greenbaum LA; Sarwal M; Grimm P; Niaudet P; Deschênes G; Cornelissen E; Morin D; Cochat P; Matossian D; Gaillard S; Bagger MJ; Rioux P
    Clin J Am Soc Nephrol; 2012 Jul; 7(7):1112-20. PubMed ID: 22554716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chitotriosidase as a Novel Biomarker for Therapeutic Monitoring of Nephropathic Cystinosis.
    Veys KRP; Elmonem MA; Van Dyck M; Janssen MC; Cornelissen EAM; Hohenfellner K; Prencipe G; van den Heuvel LP; Levtchenko E
    J Am Soc Nephrol; 2020 May; 31(5):1092-1106. PubMed ID: 32273301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of transitioning from immediate release to extended release cysteamine therapy in Norwegian patients with nephropathic cystinosis: a retrospective study.
    Bjerre A; Aase SA; Radtke M; Siva C; Gudmundsdottir H; Forsberg B; Woldseth B; Brackman D
    Pediatr Nephrol; 2023 Nov; 38(11):3671-3679. PubMed ID: 37219641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients.
    Bouazza N; Tréluyer JM; Ottolenghi C; Urien S; Deschenes G; Ricquier D; Niaudet P; Chadefaux-Vekemans B
    Orphanet J Rare Dis; 2011 Dec; 6():86. PubMed ID: 22195601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life is improved and kidney function preserved in patients with nephropathic cystinosis treated for 2 years with delayed-release cysteamine bitartrate.
    Langman CB; Greenbaum LA; Grimm P; Sarwal M; Niaudet P; Deschenes G; Cornelissen EA; Morin D; Cochat P; Elenberg E; Hanna C; Gaillard S; Bagger MJ; Rioux P
    J Pediatr; 2014 Sep; 165(3):528-33.e1. PubMed ID: 24948347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment of cystinosis in children with twice-daily cysteamine.
    Dohil R; Gangoiti JA; Cabrera BL; Fidler M; Schneider JA; Barshop BA
    J Pediatr; 2010 May; 156(5):823-7. PubMed ID: 20138296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strict cysteamine dose regimen is required to prevent nocturnal cystine accumulation in cystinosis.
    Levtchenko EN; van Dael CM; de Graaf-Hess AC; Wilmer MJ; van den Heuvel LP; Monnens LA; Blom HJ
    Pediatr Nephrol; 2006 Jan; 21(1):110-3. PubMed ID: 16252107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous cysteamine therapy for nephropathic cystinosis.
    Gahl WA; Ingelfinger J; Mohan P; Bernardini I; Hyman PE; Tangerman A
    Pediatr Res; 1995 Oct; 38(4):579-84. PubMed ID: 8559613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twice-daily cysteamine bitartrate therapy for children with cystinosis.
    Dohil R; Fidler M; Gangoiti JA; Kaskel F; Schneider JA; Barshop BA
    J Pediatr; 2010 Jan; 156(1):71-75.e1-3. PubMed ID: 19775699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cysteamine bitartrate delayed-release capsules control leukocyte cystine levels and promote statural growth and kidney health in an open-label study of treatment-naïve patients <6 years of age with nephropathic cystinosis.
    Vaisbich MH; Caires Ferreira J; Price H; Young KD; Sile S; Checani G; Langman CB
    JIMD Rep; 2022 Jan; 63(1):66-79. PubMed ID: 35028272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Human Induced Pluripotent Stem Cells and Kidney Organoids To Develop a Cysteamine/mTOR Inhibition Combination Therapy for Cystinosis.
    Hollywood JA; Przepiorski A; D'Souza RF; Sreebhavan S; Wolvetang EJ; Harrison PT; Davidson AJ; Holm TM
    J Am Soc Nephrol; 2020 May; 31(5):962-982. PubMed ID: 32198276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parenchymal organ cystine depletion with long-term cysteamine therapy.
    Gahl WA; Charnas L; Markello TC; Bernardini I; Ishak KG; Dalakas MC
    Biochem Med Metab Biol; 1992 Dec; 48(3):275-85. PubMed ID: 1476793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients.
    Belldina EB; Huang MY; Schneider JA; Brundage RC; Tracy TS
    Br J Clin Pharmacol; 2003 Nov; 56(5):520-5. PubMed ID: 14651726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cystinosis].
    Watanabe H; Kamoshita S
    Nihon Rinsho; 1992 Jul; 50(7):1593-8. PubMed ID: 1404889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of long-term cysteamine treatment in patients with cystinosis.
    Ariceta G; Giordano V; Santos F
    Pediatr Nephrol; 2019 Apr; 34(4):571-578. PubMed ID: 29260317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel sustained-release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers.
    Berends CL; Pagan L; van Esdonk MJ; Klarenbeek NB; Bergmann KR; Moerland M; van der Wel V; de Visser SJ; Büller H; de Loos F; de Vries WS; Waals H; de Leede LGJ; Burggraaf J; Kamerling IMC
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00739. PubMed ID: 33764642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.